As pharmaceutical companies have reported their earnings over the past two weeks, it’s been like staring at a foreboding sky, guessing: Will it merely drizzle? Or will there be a storm, and a flood?

The reason? Worries about drug prices. What else. As Pfizer’s new chief executive, Albert Bourla, said during a question-and-answer session with analysts: It’s “very clear that pricing is not going to be a growth driver for us now and, I think, in the future. It’s very clear.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Matthew not matter how the sentence is framed, storm clouds are here to stay. No Easing!

    Only avenue for the pharma companies that do not have/produce orphan drugs is to raise prices of the existing drugs.

    Why? Answer is simple. They do not have many new drugs that are for masses and affordable and can offset the revenue gain that companies get from price increases of existing drugs.

    Marginally better drugs that are high priced are white elephants that no one wants to use.

    Basically what all that means. Pharma’s existing business model that is OOOOLD is broken and beyond repair. Need new model that will also serve ~80% of the global population.

  • Is this sentence correct: “This means that there is a 9 percentage point difference between what a consumer would pay at the drug counter and what pharmaceutical companies received.”. There was, on average, an additional 9% differential due to the price changes, but it doesn’t mean there’s only a 9% difference. This sort of thing could happen in multiple quarters, and there was likely an initial price differential.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy